Form D · Biotechnology
SANIA THERAPEUTICS, INC.
London, X0 · CIK 0001901599
Offering snapshot reported May 21, 2024 · SEC filing
- Reported sold
- $5M Offering amount: $7.5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 6, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 21, 2024 | Initial | $4,999,995 | No comparison | 4 | SEC filing |
| Mar 8, 2023 | Initial | $1,500,000 | No comparison | 9 | SEC filing |
| Mar 23, 2022 | Initial | $5,046,995 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513793
Source: Form D, filed May 21, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Brownstone | Director |
| Raj Dattani | Director, Executive |
| Mark Evans | Director |
| Eric Kohlmann | Director |
| Joseph Korff | Director |
| Andrew Murray | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Sania Rx Ltd, Waterfront Building Manbre Wharf
London, X0, W6 9RH
London, X0, W6 9RH